Clinical Trials Logo

Clinical Trial Summary

Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Extended Release (XR; 3mgs) versus placebo on drinking measures in women with AUD.


Clinical Trial Description

Gender-specific variation in sympathetic sensitivity (Fox et al., 2014; Fox and Sinha, 2009; Cahill, 2003; Heinsbroek et al., 1991) may mean that guanfacine is particularly efficacious in attenuating drinking in women, rather than men with Alcohol Use Disorder (AUD). Thus, the investigators propose a double blind, placebo-controlled, 10-week randomized clinical trial to examine the effects of Guanfacine XR (3mgs/daily) versus placebo in 60 women with AUD. This will include twice weekly appointments comprising medical management and contingency management protocols, collection of urine, breathalyzer screens, and vitals. Measures of craving and mood will also be assessed. Parallel laboratory challenge studies will also be conducted both on admission to out-patient treatment and again following 4 weeks of treatment, in order to better elucidate the potentially therapeutic mechanisms of guanfacine. Participants will be exposed to a personal stress versus relaxing imagery condition, 1 condition per day, in a randomized order. Craving, anxiety, mood, cognitive control, heart rate and blood pressure (HRBP), and biological stress system markers will be assessed at baseline, following imagery and at various recovery timepoints. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03137082
Study type Interventional
Source Stony Brook University
Contact Antoinette Funaro, MS
Phone 631 638 0057
Email antoinette.funaro@stonybrookmedicine.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date January 2017
Completion date December 2019

See also
  Status Clinical Trial Phase
Withdrawn NCT04659278 - Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use N/A
Recruiting NCT05522075 - Reducing Blood Pressure in Mid-life Adult Binge Drinkers N/A
Completed NCT02071836 - A Web Application to Reduce Heavy Drinking in First-time DWI Offenders N/A
Completed NCT03099590 - Alkontrol-herbal Effects on Alcohol Drinking Phase 2
Completed NCT00810901 - Intervention to Motivate Teens to be a Designated Organ Donor on Driver's License N/A
Completed NCT03521115 - Family Based Prevention of Alcohol and Risky Sex for Older Teens N/A